Abstract
Although interferon (IFN) α and β are currently recognized as the most effective agents for treating patients with chronic hepatitis B and C, they are well known to cause various adverse effects. To reduce the dose of IFN necessary for treatment, we tried enhancing the effects of IFN in the liver by ultrasound exposure. Percutaneous insonation in mouse liver following IFN- β injection with the ultrasound power level used at clinical diagnosis enhanced the IFN- β -induced increase of 2',5'-oligoadenylate synthetase (2-5AS) levels in the liver. This enhancement of the 2-5AS level was dependent on the duration as well as on the timing of insonation after the IFN- β injection. In contrast, liver insonation did not enhance 2-5AS levels in the lung or spleen, and moreover, it did not alter tissue distribution of injected IFN. Thus, the combination of IFN- β administration and subsequent liver insonation appears to be a promising method for enhancing the antiviral activity of IFN specifically in the liver, enabling a reduction in the dose necessary for treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
